Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

被引：172

作者：

Ramakrishnan, Melarkode S. ^{[1
]}

Eswaraiah, Anand ^{[2
]}

Crombet, Tania ^{[3
]}

Piedra, Patricia ^{[3
]}

Saurez, Giselle ^{[3
]}

Iyer, Harish

Arvind, A. S. ^{[2
]}

机构：

[1] Biocon Ltd, Dept Res & Dev, Bangalore 560100, Karnataka, India

[2] Clinigene Int Ltd, Bangalore, Karnataka, India

[3] Ctr Mol Immunol, Havana, Cuba

来源：

MABS | 2009年 / 1卷 / 01期

关键词：

nimotuzumab; EGFR; humanized; monoclonal antibody; SCCHN; glioma; overall survival; GROWTH-FACTOR RECEPTOR; ANTIBODY; CANCER; EGFR; INHIBITORS; RADIOTHERAPY; CETUXIMAB; NECK; H-R3; HEAD;

D O I：

10.4161/mabs.1.1.7509

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different indications. Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. This review focuses on the unique functional characteristics of nimotuzumab. Also, it discusses the safety and efficacy data obtained from the Phase IIb clinical trial conducted in India in SCCHN. Post marketing surveillance data from Cuba for the use of nimotuzumab in pediatric and adult glioma is also discussed. Overall, nimotuzumab has immense therapeutic potential in cancers of epithelial origin.

引用

页码：41 / 48

页数：8

共 18 条

[1] Dermatologic side effects associated with the epidermal growth factor receptor inhibitors [J].

Agero, Anna Liza C. ;

Dusza, Stephen W. ;

Benvenuto-Andrade, Cristiane ;

Busam, Klaus J. ;

Myskowski, Patricia ;

Halpern, Allan C. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) :657-670

[2] Nimotuzumab: Evidence of clinical benefit without rash [J].

Allan, DGP .

ONCOLOGIST, 2005, 10 (09) :760-761

[3]

Arleaga ME, 2007, CANCER BIOL THER, V6, P1390

[4] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].

Bonner, JA ;

Harari, PM ;

Giralt, J ;

Azarnia, N ;

Shin, DM ;

Cohen, RB ;

Jones, CU ;

Sur, R ;

Raben, D ;

Jassem, J ;

Ove, R ;

Kies, MS ;

Baselga, J ;

Youssoufian, H ;

Amellal, N ;

Rowinsky, EK ;

Ang, KK .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578

[5] Drug therapy: EGFR antagonists in cancer treatment [J].

Ciardiello, Fortunato ;

Tortora, Giampaolo .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174

[6] Panitumumab the first fully human monoclonal antibody: from the bench to the clinic [J].

Cohenuram, Michael ;

Saif, Muhammad Wasif .

ANTI-CANCER DRUGS, 2007, 18 (01) :7-15

[7] Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients [J].

Crombet, T ;

Osorio, M ;

Cruz, T ;

Roca, C ;

del Castillo, R ;

Mon, R ;

Iznaga-Escobar, N ;

Figueredo, R ;

Koropatnick, J ;

Renginfo, E ;

Fernández, E ;

Alvárez, D ;

Torres, O ;

Ramos, M ;

Leonard, I ;

Pérez, R ;

Lage, A .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1646-1654

[8] Antiproliferative, antiangiogenic and proapoptotic activity of h-R3:: A humanized anti-EGFR antibody [J].

Crombet-Ramos, T ;

Rak, J ;

Pérez, R ;

Viloria-Petit, A .

INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (06) :567-575

[9] A NEW MONOCLONAL-ANTIBODY FOR DETECTION OF EGF-RECEPTORS IN WESTERN BLOTS AND PARAFFIN-EMBEDDED TISSUE-SECTIONS [J].

FERNANDEZ, A ;

SPITZER, E ;

PEREZ, R ;

BOEHMER, FD ;

ECKERT, K ;

ZSCHIESCHE, W ;

GROSSE, R .

JOURNAL OF CELLULAR BIOCHEMISTRY, 1992, 49 (02) :157-165

[10] ERBB receptors and cancer: The complexity of targeted inhibitors [J].

Hynes, NE ;

Lane, HA .

NATURE REVIEWS CANCER, 2005, 5 (05) :341-354

← 1 2 →